E-COLI
Escherichia coli (E. coli) Overview
Diseases
Urinary Tract Infections (UTI):
E. coli is the predominant cause of both community-acquired and healthcare-associated urinary tract infections, accounting for approximately 80-85% of cases.
Symptoms include dysuria, urgency, frequency of urination, and suprapubic pain. In cases of pyelonephritis, flank pain and fever may also be present.
Sepsis:
E. coli is a leading cause of sepsis, particularly among hospitalized patients and those with weakened immune systems.
It can enter the bloodstream through urinary tract infections, intra-abdominal infections, or pneumonia, leading to systemic inflammatory response syndrome (SIRS).
Neonatal Meningitis:
E. coli is one of the major bacterial pathogens responsible for meningitis in newborns, particularly strains encapsulated with the K1 antigen.
Risk factors include prematurity, low birth weight, and prolonged rupture of membranes.
Diarrhea:
Traveler’s Diarrhea: Caused mainly by enterotoxigenic E. coli (ETEC), which produces heat-labile (LT) and heat-stable (ST) toxins, resulting in watery diarrhea that is typically self-limiting and brief in duration.
Enterohemorrhagic E. coli (EHEC): Notably the O157:H7 strain, which produces Shiga toxin, causing severe abdominal cramping, bloody diarrhea, and complications like hemolytic-uremic syndrome (HUS), which can lead to acute kidney failure. This pathogen is often linked to contaminated food and water sources.
Pathogenesis
Reservoirs:
E. coli resides in the intestines of healthy humans and animals. Certain strains, such as O157:H7, are associated with cattle, highlighting the zoonotic nature of some pathogenic strains.
Key Factors:
Pili:
Specialized structures that facilitate adherence to uroepithelial cells in the urinary tract, critical for the development of UTIs. P fimbriae are particularly significant in ascending infections.
Capsule:
A polysaccharide layer that helps E. coli evade phagocytosis by immune cells, enhancing its virulence during infections.
Toxins:
Heat-labile Toxin (LT):
Stimulates adenylate cyclase, increasing cAMP levels in enterocytes, leading to secretion of water and electrolytes, hence causing diarrhea.
Heat-stable Toxin (ST):
Activates guanylate cyclase, increasing cGMP levels, contributing to fluid secretion.
Shiga Toxin:
Produced by EHEC, it inhibits protein synthesis in host cells, contributing to bloody diarrhea and the characteristic effects of HUS, such as hemolytic anemia and acute renal failure.
Clinical Features
Intestinal Infections:
Traveler’s Diarrhea (ETEC):
Typically presents with watery, non-bloody diarrhea, abdominal cramps, and mild fever for a duration of 3-7 days.
Bloody Diarrhea (EHEC):
Characterized by severe abdominal pain, bloody stools, and potential for HUS, manifesting with symptoms like pallor, oliguria, and petechiae due to kidney involvement.
Extraintestinal Infections:
UTI:
Symptoms include dysuria, urgency, increased frequency, and possible flank pain. In cases of pyelonephritis, systemic symptoms like fever and chills may be present.
Neonatal Meningitis:
Symptoms may include fever, irritability, poor feeding, and signs of increased intracranial pressure (e.g., bulging fontanelle).
Sepsis:
Clinical manifestations typically include fever, chills, hypotension, elevated heart rate, and potential multi-organ dysfunction due to systemic spread of infection.
Diagnosis
Lab Features:
Lactose Fermentation:
E. coli ferments lactose, producing pink colonies on MacConkey agar and a green metallic sheen on Eosin Methylene Blue (EMB) agar.
EHEC Identification:
Identified through sorbitol non-fermentation on MacConkey agar (specific for O157:H7 strains).
Clinical Tests:
Urine cultures confirm UTIs, with >100,000 CFU/mL indicative of infection. Blood cultures are essential in sepsis diagnosis, while stool cultures and serotyping are necessary for gastrointestinal infections.
Treatment
UTIs:
First-line treatments include oral trimethoprim-sulfamethoxazole and nitrofurantoin for uncomplicated cystitis.
In cases of pyelonephritis, fluoroquinolones such as ciprofloxacin may be administered.
Sepsis:
Empirical therapy with broad-spectrum parenteral antibiotics (e.g., cefotaxime +/- gentamicin) is critical, with adjustments based on culture results.
Neonatal Meningitis:
Treatment involves high-dose ampicillin combined with cefotaxime to cover for both E. coli and listeria monocytogenes.
Diarrhea:
Supportive care is essential; antibiotics are contraindicated in EHEC infections due to the increased risk of HUS. Fluid replacement and rehydration are crucial.
Prevention
General Measures:
Individuals should avoid undercooked meats, unpasteurized dairy products, and contaminated water. Proper food handling and hygiene practices are crucial, especially during food preparation.
Catheter management is important in healthcare settings; they should be used judiciously and removed as soon as they are no longer necessary to prevent urinary tract infections.
Dietary measures, such as cranberry juice, may help inhibit E. coli by preventing the adhesion of bacteria to the urinary tract lining.
For travelers, prophylactic antibiotics or the use of bismuth subsalicylate (Pepto-Bismol) prior to travel can help prevent travel-associated diarrhea, alongside careful food choices to avoid exposure